Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;8(6):2840-2857.
doi: 10.1002/cam4.2186. Epub 2019 Apr 23.

Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes

Qi-Qi Liu  1   2 , He-Fen Sun  1   2 , Xue-Li Yang  1   2 , Meng-Ting Chen  1   2 , Yang Liu  1   2 , Yang Zhao  1   2 , Yuan-Yuan Zhao  1   2 , Wei Jin  1   2
Affiliations

Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes

Qi-Qi Liu et al. Cancer Med. 2019 Jun.

Abstract

Background: To evaluate the significance and benefit of radiotherapy (RT) in young early-stage breast cancer patients according to different molecular subtypes.

Methods: We conducted a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results database with known hormone receptor (HoR) and human epidermal growth factor receptor 2 (HER2) status. Female patients aged 18-45, received RT treatment, and diagnosed with stage T1-3, N0-3, M0 primary breast cancer between 2010 and 2013 were identified.

Results: Of all the 23 148 included patients, 14 708 (63.54%), 3385 (14.62%), 1225 (5.29%), and 3830 (16.55%) were diagnosed with luminal-A (HoR + HER2-), luminal-B (HoR + HER2+), HER2-enriched (HoR-HER2+), and triple-negative (HoR-HER2-) breast cancer, respectively. RT was significantly correlated with improved overall survival (OS, HR: 0.295; 95% CI:0.138-0.63, P = 0.002) and breast cancer-specific survival (BCSS, HR: 0.328; 95% CI: 0.153-0.702, P = 0.004) in HER2-enriched patients. In addition, a significantly prolonged OS was also observed when RT was given to luminal-A (HR: 0.696; 95% CI: 0.538-0.902, P = 0.006) and luminal-B (HR: 0.385; 95% CI:0.199-0.744, P = 0.005) breast cancer patients compared to those without RT. Multivariable-adjusted analyses showed that HER2 was a significant favorable factor for RT benefit in breast cancer patients.

Conclusions: RT could offer significant survival benefit in luminal-A, luminal-B, and especially HER2-enriched young early-stage breast cancer female patients. The results enabled clinicians to predict the benefits of RT and improve evidence-based treatment for breast cancer patients.

Keywords: breast cancer; molecular subtype; radiation therapy; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan‐Meier curve of overall survival (A) and breast cancer‐specific survival (B) in the whole early‐stage breast cancer patients
Figure 2
Figure 2
Kaplan‐Meier curve of overall survival in patients with luminal A (A), luminal B (B), HER2‐enriched (C) and triple negative (D) early‐stage breast cancer
Figure 3
Figure 3
Kaplan‐Meier curve of breast cancer‐specific survival in patients with luminal A (A), luminal B (B), HER2‐enriched (C) and triple negative (D) early‐stage breast cancer
Figure 4
Figure 4
Hazard ratio and 95% confidence interval for overall survival (A) and breast cancer‐specific survival (B) according to the receipt of radiotherapy in the subgroup of patients for each characteristic
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Centers for Disease Control and Prevention . CDC breast cancer rates by race and ethnicity, 2014. www.cdc.gov/cancer/breast/statistics/race.htm. Accessed June 23, 2016.
    1. Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: Status and determinants. Womens Health (Lond). 2011;7:677‐687. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2019. 10.3322/caac.21551. - DOI - PubMed
    1. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324‐3330. 10.1200/JCO.2007.14.2471. - DOI - PubMed
    1. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early‐stage disease. J Am Coll Surg. 2009;208:341‐347. - PMC - PubMed

Publication types

MeSH terms

Substances